Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vaccines developer Stressgen Biotechnologies has revealed that it will almost halve its workforce, as part of restructuring measures to focus on advancing its lead product candidate to market.
Subscribe to our email newsletter
The company said the move will enable it to focus its resources on the advancement of HspE7 for human papillomavirus (HPV)-related diseases. As a result of the restructuring, Stressgen will reduce its workforce by approximately 49% from 77 to 39 employees, and redirect its research efforts in order to reduce annual cash expenditures.
As part of the restructuring, the company will consolidate its US offices by closing the Collegeville, Pennsylvania facility by year-end. The restructuring activities are expected to cut the company’s baseline burn rate over time by around C$5 million per year.
Going forward, Stressgen will dedicate its strategic and financial resources to support the further advancement of HspE7. All R&D activities not related to the HspE7 program will be deferred and the company will accelerate its efforts to form partnerships for the compound.